picropodophyllin has been researched along with Epithelial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, X; Lv, J; Mei, J; Wang, L; Wang, X; Zhang, Q; Zhu, X | 1 |
| Chaudhury, S; Gaikwad, SM; Jinager, A; Maheshwari, A; Ray, P; Singh, RK | 1 |
2 other study(ies) available for picropodophyllin and Epithelial Neoplasms
| Article | Year |
|---|---|
Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Growth Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Podophyllotoxin; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Podophyllotoxin; Proteasome Endopeptidase Complex; Receptor, IGF Type 1 | 2014 |